Intra-cellular therapies announces positive phase 3 topline results from study 501 evaluating lumateperone as adjunctive therapy in patients with major depressive disorder

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints

ITCI Ratings Summary

ITCI Quant Ranking